Stockscreener 앱 받기
4.665
1.97%
0.095
전일 마감가:
$4.57
열려 있는:
$4.6
하루 거래량:
432.10K
Relative Volume:
0.38
시가총액:
$296.20M
수익:
$157.08M
순이익/손실:
$-70.36M
주가수익비율:
-4.1967
EPS:
-1.1116
순현금흐름:
$-71.69M
1주 성능:
+0.87%
1개월 성능:
+19.18%
6개월 성능:
+157.46%
1년 성능:
+242.65%
1일 변동 폭
$4.39
$4.72
1주일 범위
$4.39
$5.06
52주 변동 폭
$1.29
$5.08
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
4.66 | 299.38M | 157.08M | -70.36M | -71.69M | -1.1116 |
VRTX
Vertex Pharmaceuticals Inc
|
524.45 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.19 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
922.74 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.83 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.52 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2024-11-07 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-05-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-04-26 | 개시 | B. Riley Securities | Buy |
| 2024-04-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-03-04 | 재확인 | BTIG Research | Buy |
| 2024-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-04 | 개시 | SMBC Nikko | Outperform |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
| 2020-12-22 | 재개 | H.C. Wainwright | Buy |
| 2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Guggenheim | Neutral |
| 2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
| 2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-05-31 | 개시 | Evercore ISI | Outperform |
| 2018-03-05 | 개시 | H.C. Wainwright | Buy |
| 2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations - The Sun Malaysia
MacroGenics completes sale of manufacturing operations to Bora - Investing.com
MacroGenics sells its drug-making operations to Bora for $122.5M - Stock Titan
MacroGenics (MGNX) Financials 2026Income Statement and Balance Sheet - MarketBeat
Macrogenics | 4: Statement of changes in beneficial ownership of securities-Director O'Brien Federica F. - Moomoo
MacroGenics, Inc.(NasdaqGS:MGNX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2500 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Value Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 2000 Growth Benchmark - marketscreener.com
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Index - marketscreener.com
Enterprise value to revenue forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
MacroGenics, Inc.(NasdaqGS: MGNX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to revenue forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBITDA forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Enterprise value to EBIT forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
Price to sales forward of MacroGenics, Inc. – NASDAQ:MGNX - TradingView
Price to book forward of MacroGenics, Inc. – BOATS:MGNX - TradingView
MGNX Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics, Inc. Actuals & Estimates (NASDAQ:MGNX) - TradingView
M55 Forecast — Price Target — Prediction for 2027 - TradingView
A1W6ND Forecast — Price Target — Prediction for 2027 - TradingView
MacroGenics Inc (MGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX) - Seeking Alpha
MacroGenics To Receive $24.5 Million Milestone From Sanofi For TZIELD Approval - Pulse 2.0
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval - The Manila Times
MacroGenics stock rises on $24.5M Sanofi milestone payment - Investing.com
MacroGenics to receive $24.5M milestone from Sanofi on FDA approval - Investing.com Australia
MacroGenics stock rises on $24.5M Sanofi milestone payment By Investing.com - Investing.com Nigeria
Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics - GuruFocus
MacroGenics to Receive $24.5 Million in Regulatory Milestone Payment - marketscreener.com
MacroGenics to Receive $24.5 Million Milestone Payment Following FDA Accelerated Approval of Sanofi’s TZIELD for Children with Stage 3 Type 1 Diabetes - Quiver Quantitative
Sanofi’s TZIELD approval triggers $24.5M payment to MacroGenics - Stock Titan
MacroGenics (MGNX) Gains 4.3% as Shares Test Key Resistance LevelsOrder Block - dars.gov.et
MacroGenics Inc (MGNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MacroGenics StockThursday technical snapshot after strong year-to-date rebound - AD HOC NEWS
MacroGenics Inc (MGNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MacroGenics Inc (MGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
MacroGenics Inc (MGNX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MacroGenics Inc (MGNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MacroGenics Inc Stock (US5562221046): Valuation metrics in focus after recent biotech swing - Ad-hoc-news.de
How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks - Yahoo Finance
Millennium Group and Israel Englander report 3.44M MGNX shares (5.4%) - Stock Titan
MacroGenics eyes $200M cash boost, 2028 runway ahead of cancer pipeline updates - MSN
MacroGenics (MGNX) Slips 1.19% as Biotech Stock Tests Key SupportPoint of Control - Město Břeclav
MacroGenics expands ZYNYZ royalty deal with Sagard, secures $60M upfront - MSN
MacroGenics Inc stock (US5562221046): shares ease after strong year-to-date run amid biotech volatil - AD HOC NEWS
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Macrogenics Inc 주식 (MGNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 19 '25 |
Buy |
1.52 |
50,500 |
76,760 |
61,500 |
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
1.98%
3.59%
자본화:
|
볼륨(24시간):